According to the Zhitong Finance App, Okanvision Bio-B (01477.HK) announced that the group's fluoroclide intravitreal implants have recently been approved by the China Drug Administration for production in mainland China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.